Autolus Therapeutics Secures $250 Million Financing as Cancer Drug Sales Surge
London, Monday, 3 August 2026.
Autolus Therapeutics has secured a $250 million credit facility from Perceptive Advisors following a 70% quarterly sales jump for its cancer therapy AUCATZYL. Driven by expanding treatment center adoption, the company’s gross margins surged to 35% in the first half of 2026—a dramatic turnaround from negative 20% in late 2025—prompting management to raise full-year revenue guidance to $150 million and extend its cash runway into 2028.
Strategic Financing Agreement
On July 30, 2026, Autolus Therapeutics closed a five-year, interest-only senior credit facility with Perceptive Advisors [1]. The agreement includes an initial principal amount of $75 million funded at closing, with an option for an additional $25 million available for up to six months post-closing [1]. Further tranches totaling $150 million are available based on specific revenue milestones, bringing the total potential value to $250 million [1].
Strategic Financing Agreement
Management stated that the strategic financing provides additional capital to support key inflection points, including clinical data milestones in oncology and autoimmune development programs [1]. The company confirmed that the current funding provides a cash runway into the second quarter of 2028 [1]. This capitalization supports the commercial ramp-up of its cell therapy platform amidst ongoing investment dynamics in the advanced biotechnology sector [1].
Updated Guidance and Clinical Pipeline
Autolus increased its fiscal year 2026 sales guidance to a range of $140 million to $150 million, raised from previous guidance of $120 million to $135 million [1]. The width of the new guidance range is 10 million [1]. The company is actively pursuing commercialization and manufacturing expansion of AUCATZYL for adult r/r B-ALL into additional territories [1]. Additionally, the company is developing obe-cel for autoimmune indications, specifically Lupus Nephritis and progressive Multiple Sclerosis [1].
Updated Guidance and Clinical Pipeline
Autolus is scheduled to report full second quarter 2026 financial results on August 11, 2026 [1]. Some market trackers had previously noted an event date of August 10, 2026, highlighting the importance of verifying dates with primary filings [2][3]. Management anticipates meeting financial milestones under the new Credit Facility to unlock remaining tranches and secure interest margin reductions [1].